Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs).

导出 LinkOut

翻译打印收藏纠错

作者： Irene,Zinonos ^[1] ; Agatha,Labrinidis ^[1] ; Vasilios,Liapis ^[1] ; Shelley,Hay ^[1] ; Vasilios,Panagopoulos ^[1] ; Mark,Denichilo ^[1] ; Vladimir,Ponomarev ^[2] ; Wendy,Ingman ^[3] ; Gerald J,Atkins ^[4] ; David M,Findlay ^[4] ; Andrew C W,Zannettino ^[5] ; Andreas,Evdokiou ^[6]

作者单位： Discipline of Surgery, Breast Cancer Research Unit, Basil Hetzel Institute and Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide, SA, Australia. ^[1] Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A. ^[2] Discipline of Surgery, Haematology - Oncology, Breast Biology Cancer Unit, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia. ^[3] Discipline of Orthopaedics and Trauma, University of Adelaide, Adelaide, SA, Australia. ^[4] Myeloma Research Laboratory, School of Medical Sciences, Faculty of Health Science and Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide, SA, Australia. ^[5] Discipline of Surgery, Breast Cancer Research Unit, Basil Hetzel Institute and Centre for Personalised Cancer Medicine, University of Adelaide, Adelaide, SA, Australia andreas.evdokiou@adelaide.edu.au. ^[6]

关键词 Apo2L/TRAIL Apoptosis breast cancer chemotherapy drozitumab drug resistance